Clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health.
Context
What happened: Helus Pharma Inc. (HELP) held an investor presentation on October 21, 2026, discussing its clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health. CEO Michael Halstead opened the call after a forward-looking statements disclaimer.
Key numbers: Presentation dated October 21, 2026, 9:00 AM EDT.
Why it matters: The call covered Phase 3 strategies for the company's serotonergic agonist programs, with participation from analysts at TD Cowen, Jefferies, Canaccord Genuity, Cantor Fitzgerald, Guggenheim Securities, and H.C. Wainwright.
What changed
Helus Pharma Inc. (HELP) held an investor presentation on October 21, 2026, discussing its clinical pipeline and Phase 3 strategies for novel serotonergic agonists in mental health. CEO Michael Halstead opened the call after a forward-looking statements disclaimer.
Why it matters
The call covered Phase 3 strategies for the company's serotonergic agonist programs, with participation from analysts at TD Cowen, Jefferies, Canaccord Genuity, Cantor Fitzgerald, Guggenheim Securities, and H.C. Wainwright.
← Dashboard
Oct 23, 2026 11:48 PM ET